Share Price and Basic Stock Data
Last Updated: October 9, 2025, 11:31 pm
| PEG Ratio | 0.48 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Vaxtex Cotfab Ltd, a company with a market capitalization of ₹18.0 Cr., operates in an industry not specified in the data provided. Looking at the quarterly and annual sales trends, the company’s revenue figures show stability, with a consistent pattern of sales growth. However, it’s essential to delve deeper into the expense structure to understand the impact on operating profits. By analyzing the data further, we can uncover insights into the company’s core business operations and market positioning, shedding light on its competitive standing within the industry.
Profitability and Efficiency Metrics
The company’s operating profit margin (OPM) remains a crucial metric in assessing its efficiency, alongside net profit, return on equity (ROE), return on capital employed (ROCE), and interest coverage ratio (ICR). With an OPM not provided in the data, we rely on other metrics like ROE and ROCE to gauge profitability and operational efficiency. A ROE of 4.74% and ROCE of 1.77% indicate a moderate performance compared to sector benchmarks. The interest coverage ratio of 5.58x reflects a comfortable position regarding debt obligations. However, the cash conversion cycle of 971.94 days warrants a closer look at the company’s working capital management.
Balance Sheet Strength and Financial Ratios
Examining the balance sheet, the company shows negative reserves of -₹0.04 Cr. and borrowings amounting to ₹11.13 Cr. The low price-to-book value (P/BV) ratio of 0.65x suggests a potential undervaluation in the market. Additionally, the interest coverage ratio of 5.58x indicates a healthy ability to meet interest payments. However, the negative reserves and significant borrowings point towards a strained financial position, warranting a thorough evaluation of the company’s debt structure and liquidity position.
Shareholding Pattern and Investor Confidence
The shareholding pattern reveals that promoters hold 16.47% of the company, while FIIs have no stake, and DIIs data is not available. Public shareholding stands at 83.53%, indicating a broad investor base with 41,807 shareholders. Changes in promoter holdings can signal shifts in confidence, impacting market perception and valuation. The absence of FII holdings may raise questions about foreign investor interest in the company. Analyzing these trends over time can provide valuable insights into investor sentiment and its influence on the stock’s performance.
Outlook, Risks, and Final Insight
Looking ahead, Vaxtex Cotfab Ltd’s growth prospects hinge on key drivers such as expanding market presence, enhancing operational efficiency, and prudent financial management to address debt concerns. Risks include economic uncertainties, industry competition, and liquidity challenges due to the cash conversion cycle. Strengthening operational efficiency, reducing debt burden, and fostering investor confidence through transparent communication could bolster future performance. In conclusion, a balanced approach to monitoring financial health, operational metrics, and investor sentiment is crucial for a comprehensive evaluation of the company’s potential trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Vaxtex Cotfab Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 152 Cr. | 39.4 | 875/31.9 | 1.48 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,636 Cr. | 194 | 227/124 | 101 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 59.2 Cr. | 4.64 | 8.90/4.53 | 5.12 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,558.26 Cr | 262.54 | 398.28 | 100.80 | 0.22% | 11.73% | 22.92% | 9.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.33 | 18.33 | 11.39 | 16.57 | 10.84 | 4.10 | 2.08 | -0.40 | 0.00 | 0.00 | 0.00 | 5.25 | 0.00 |
| Expenses | 28.86 | 17.91 | 12.82 | 16.43 | 10.30 | 3.93 | 10.72 | 0.82 | -0.09 | 0.11 | 0.37 | 5.34 | 0.21 |
| Operating Profit | 0.47 | 0.42 | -1.43 | 0.14 | 0.54 | 0.17 | -8.64 | -1.22 | 0.09 | -0.11 | -0.37 | -0.09 | -0.21 |
| OPM % | 1.60% | 2.29% | -12.55% | 0.84% | 4.98% | 4.15% | -415.38% | -1.71% | |||||
| Other Income | 0.64 | 0.11 | 1.57 | 0.16 | 0.05 | 0.01 | 0.02 | 0.44 | 0.02 | 0.03 | 0.01 | 1.06 | 0.46 |
| Interest | 0.28 | 0.36 | -0.02 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.06 | 0.02 |
| Depreciation | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.00 | 0.00 | 0.01 | 0.01 | 0.06 | 0.01 | 0.01 |
| Profit before tax | 0.76 | 0.10 | 0.09 | 0.23 | 0.50 | 0.09 | -8.63 | -0.79 | 0.08 | -0.11 | -0.44 | 0.90 | 0.22 |
| Tax % | 0.00% | 0.00% | 0.00% | 13.04% | 26.00% | 22.22% | 0.00% | -18.99% | 0.00% | 0.00% | -11.36% | -47.78% | 0.00% |
| Net Profit | 0.77 | 0.10 | 0.09 | 0.21 | 0.37 | 0.07 | -8.63 | -0.65 | 0.08 | -0.12 | -0.39 | 1.32 | 0.22 |
| EPS in Rs | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | -0.47 | -0.04 | 0.00 | -0.01 | -0.02 | 0.07 | 0.01 |
Last Updated: August 20, 2025, 1:30 am
Below is a detailed analysis of the quarterly data for Vaxtex Cotfab Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.25 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 5.25 Cr..
- For Expenses, as of Jun 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.34 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 5.13 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Mar 2025) to -0.21 Cr., marking a decrease of 0.12 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -1.71% (Mar 2025) to 0.00%, marking an increase of 1.71%.
- For Other Income, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.60 Cr..
- For Interest, as of Jun 2025, the value is 0.02 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.22 Cr.. The value appears to be declining and may need further review. It has decreased from 0.90 Cr. (Mar 2025) to 0.22 Cr., marking a decrease of 0.68 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -47.78% (Mar 2025) to 0.00%, marking an increase of 47.78%.
- For Net Profit, as of Jun 2025, the value is 0.22 Cr.. The value appears to be declining and may need further review. It has decreased from 1.32 Cr. (Mar 2025) to 0.22 Cr., marking a decrease of 1.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.07 (Mar 2025) to 0.01, marking a decrease of 0.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:31 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.63 | 4.43 | 18.45 | 21.97 | 27.76 | 26.15 | 61.91 | 75.62 | 16.62 | 5.25 |
| Expenses | 0.00 | 0.01 | 0.65 | 4.41 | 18.08 | 21.03 | 26.39 | 24.71 | 58.90 | 75.77 | 23.11 | 5.75 |
| Operating Profit | 0.00 | -0.01 | -0.02 | 0.02 | 0.37 | 0.94 | 1.37 | 1.44 | 3.01 | -0.15 | -6.49 | -0.50 |
| OPM % | -3.17% | 0.45% | 2.01% | 4.28% | 4.94% | 5.51% | 4.86% | -0.20% | -39.05% | -9.52% | ||
| Other Income | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | 0.05 | 0.02 | 0.06 | 0.38 | 2.22 | -2.12 | 1.13 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 1.06 | 1.09 | 1.08 | 0.63 | 0.07 | 0.11 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.11 | 0.14 | 0.15 | 0.30 | 0.28 | 0.15 | 0.10 |
| Profit before tax | 0.00 | 0.00 | 0.01 | 0.04 | 0.27 | 0.87 | 0.19 | 0.26 | 2.01 | 1.16 | -8.83 | 0.42 |
| Tax % | 0.00% | 50.00% | 37.04% | 31.03% | 52.63% | 30.77% | 26.37% | 2.59% | 0.00% | -111.90% | ||
| Net Profit | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 0.60 | 0.09 | 0.18 | 1.49 | 1.13 | -8.83 | 0.88 |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 0.60 | 0.01 | 0.01 | 0.10 | 0.06 | -0.48 | 0.05 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 750.00% | 252.94% | -85.00% | 100.00% | 727.78% | -24.16% | -881.42% | 109.97% |
| Change in YoY Net Profit Growth (%) | 0.00% | 650.00% | -497.06% | -337.94% | 185.00% | 627.78% | -751.94% | -857.25% | 991.38% |
Vaxtex Cotfab Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -28% |
| 3 Years: | -56% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | -16% |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -17% |
| 3 Years: | -53% |
| 1 Year: | 49% |
| Return on Equity | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -5% |
| 3 Years: | -10% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: September 10, 2025, 2:47 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 6.02 | 6.02 | 10.04 | 12.63 | 18.38 | 18.38 |
| Reserves | 3.53 | 3.53 | 3.53 | 3.55 | 3.72 | 4.33 | 2.63 | 2.85 | 0.32 | 10.85 | 0.42 | -0.04 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 3.29 | 12.62 | 10.30 | 7.45 | 5.20 | 11.51 | 11.13 |
| Other Liabilities | 0.03 | 0.00 | 0.27 | 0.75 | 5.82 | 5.49 | 6.65 | 2.52 | 6.18 | 40.80 | 18.56 | 19.00 |
| Total Liabilities | 3.96 | 3.93 | 4.20 | 4.70 | 10.19 | 13.51 | 27.92 | 21.69 | 23.99 | 69.48 | 48.87 | 48.47 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.36 | 1.70 | 1.80 | 2.37 | 3.85 | 3.90 | 3.65 | 1.14 | 1.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.89 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.08 | 1.05 | 1.10 | 7.01 | 7.54 |
| Other Assets | 3.07 | 3.88 | 4.20 | 4.34 | 8.49 | 11.71 | 25.43 | 17.76 | 19.04 | 64.73 | 40.72 | 39.89 |
| Total Assets | 3.96 | 3.93 | 4.20 | 4.70 | 10.19 | 13.51 | 27.92 | 21.69 | 23.99 | 69.48 | 48.87 | 48.47 |
Below is a detailed analysis of the balance sheet data for Vaxtex Cotfab Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 18.38 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 18.38 Cr..
- For Reserves, as of Mar 2025, the value is -0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.42 Cr. (Mar 2024) to -0.04 Cr., marking a decrease of 0.46 Cr..
- For Borrowings, as of Mar 2025, the value is 11.13 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 11.51 Cr. (Mar 2024) to 11.13 Cr., marking a decrease of 0.38 Cr..
- For Other Liabilities, as of Mar 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.56 Cr. (Mar 2024) to 19.00 Cr., marking an increase of 0.44 Cr..
- For Total Liabilities, as of Mar 2025, the value is 48.47 Cr.. The value appears to be improving (decreasing). It has decreased from 48.87 Cr. (Mar 2024) to 48.47 Cr., marking a decrease of 0.40 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.14 Cr. (Mar 2024) to 1.04 Cr., marking a decrease of 0.10 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 7.54 Cr.. The value appears strong and on an upward trend. It has increased from 7.01 Cr. (Mar 2024) to 7.54 Cr., marking an increase of 0.53 Cr..
- For Other Assets, as of Mar 2025, the value is 39.89 Cr.. The value appears to be declining and may need further review. It has decreased from 40.72 Cr. (Mar 2024) to 39.89 Cr., marking a decrease of 0.83 Cr..
- For Total Assets, as of Mar 2025, the value is 48.47 Cr.. The value appears to be declining and may need further review. It has decreased from 48.87 Cr. (Mar 2024) to 48.47 Cr., marking a decrease of 0.40 Cr..
However, the Borrowings (11.13 Cr.) are higher than the Reserves (-0.04 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -0.01 | -0.02 | 0.02 | 0.12 | -2.35 | -11.25 | -8.86 | -4.44 | -5.35 | -18.00 | -11.63 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 121.67 | 139.24 | 60.93 | 78.08 | 112.42 | 136.65 | 36.49 | 87.94 | 345.02 | 971.94 | ||
| Inventory Days | 64.04 | 35.35 | 35.24 | 15.72 | 70.56 | 28.50 | 36.53 | 6.96 | 3.50 | 0.00 | ||
| Days Payable | 160.09 | 53.91 | 133.87 | 127.24 | 104.80 | 36.50 | 35.52 | 152.60 | 293.74 | |||
| Cash Conversion Cycle | 25.61 | 120.68 | -37.69 | -33.44 | 78.17 | 128.65 | 37.51 | -57.70 | 54.78 | 971.94 | ||
| Working Capital Days | 28.97 | 290.02 | 45.30 | 15.78 | 88.09 | 211.04 | 68.04 | 116.08 | 458.56 | 1,177.04 | ||
| ROCE % | 0.00% | 0.00% | 0.25% | 1.02% | 6.49% | 14.21% | 8.54% | 6.68% | 16.71% | 2.02% | -20.72% | 1.77% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 2.00 | 10.00 |
| Basic EPS (Rs.) | 0.05 | -0.59 | 0.11 | 0.30 | 0.30 |
| Diluted EPS (Rs.) | 0.05 | -0.59 | 0.11 | 0.30 | 0.30 |
| Cash EPS (Rs.) | 0.05 | -0.47 | 0.11 | 0.35 | 0.54 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.99 | 1.02 | 1.86 | 2.06 | 14.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.99 | 1.02 | 1.86 | 2.06 | 14.73 |
| Revenue From Operations / Share (Rs.) | 0.28 | 0.90 | 5.99 | 12.33 | 43.42 |
| PBDIT / Share (Rs.) | 0.03 | -0.46 | 0.04 | 0.67 | 2.49 |
| PBIT / Share (Rs.) | 0.02 | -0.47 | 0.01 | 0.61 | 2.24 |
| PBT / Share (Rs.) | 0.02 | -0.48 | 0.09 | 0.40 | 0.43 |
| Net Profit / Share (Rs.) | 0.04 | -0.48 | 0.08 | 0.29 | 0.29 |
| PBDIT Margin (%) | 11.96 | -51.83 | 0.67 | 5.46 | 5.72 |
| PBIT Margin (%) | 9.97 | -52.75 | 0.30 | 4.98 | 5.15 |
| PBT Margin (%) | 7.83 | -53.15 | 1.53 | 3.24 | 1.00 |
| Net Profit Margin (%) | 16.81 | -53.15 | 1.49 | 2.39 | 0.68 |
| Return on Networth / Equity (%) | 4.81 | -47.01 | 4.82 | 14.34 | 2.00 |
| Return on Capital Employeed (%) | 2.03 | -30.18 | 0.80 | 18.53 | 7.04 |
| Return On Assets (%) | 1.82 | -18.07 | 1.62 | 6.19 | 0.82 |
| Long Term Debt / Equity (X) | 0.40 | 0.53 | 0.22 | 0.58 | 1.14 |
| Total Debt / Equity (X) | 0.60 | 0.61 | 0.22 | 0.71 | 1.16 |
| Asset Turnover Ratio (%) | 0.10 | 0.28 | 1.62 | 2.71 | 1.05 |
| Current Ratio (X) | 1.80 | 2.11 | 1.62 | 2.72 | 5.11 |
| Quick Ratio (X) | 1.80 | 2.10 | 1.59 | 1.99 | 4.44 |
| Inventory Turnover Ratio (X) | 0.00 | 26.64 | 19.63 | 16.24 | 7.54 |
| Interest Coverage Ratio (X) | 5.58 | -130.94 | 0.81 | 3.15 | 1.38 |
| Interest Coverage Ratio (Post Tax) (X) | 8.85 | -133.26 | 0.32 | 2.38 | 1.16 |
| Enterprise Value (Cr.) | 23.07 | 28.95 | 32.88 | 125.26 | 36.65 |
| EV / Net Operating Revenue (X) | 4.39 | 1.74 | 0.43 | 2.02 | 1.40 |
| EV / EBITDA (X) | 36.72 | -3.36 | 64.30 | 37.03 | 24.46 |
| MarketCap / Net Operating Revenue (X) | 2.27 | 1.05 | 0.36 | 1.91 | 1.01 |
| Price / BV (X) | 0.65 | 0.92 | 1.18 | 11.39 | 2.98 |
| Price / Net Operating Revenue (X) | 2.27 | 1.05 | 0.36 | 1.91 | 1.01 |
| EarningsYield | 0.07 | -0.50 | 0.04 | 0.01 | 0.01 |
After reviewing the key financial ratios for Vaxtex Cotfab Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.59 (Mar 24) to 0.05, marking an increase of 0.64.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.59 (Mar 24) to 0.05, marking an increase of 0.64.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has increased from -0.47 (Mar 24) to 0.05, marking an increase of 0.52.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.99. It has decreased from 1.02 (Mar 24) to 0.99, marking a decrease of 0.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.99. It has decreased from 1.02 (Mar 24) to 0.99, marking a decrease of 0.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.28. It has decreased from 0.90 (Mar 24) to 0.28, marking a decrease of 0.62.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has increased from -0.46 (Mar 24) to 0.03, marking an increase of 0.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from -0.47 (Mar 24) to 0.02, marking an increase of 0.49.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from -0.48 (Mar 24) to 0.02, marking an increase of 0.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 2. It has increased from -0.48 (Mar 24) to 0.04, marking an increase of 0.52.
- For PBDIT Margin (%), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from -51.83 (Mar 24) to 11.96, marking an increase of 63.79.
- For PBIT Margin (%), as of Mar 25, the value is 9.97. This value is below the healthy minimum of 10. It has increased from -52.75 (Mar 24) to 9.97, marking an increase of 62.72.
- For PBT Margin (%), as of Mar 25, the value is 7.83. This value is below the healthy minimum of 10. It has increased from -53.15 (Mar 24) to 7.83, marking an increase of 60.98.
- For Net Profit Margin (%), as of Mar 25, the value is 16.81. This value exceeds the healthy maximum of 10. It has increased from -53.15 (Mar 24) to 16.81, marking an increase of 69.96.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 15. It has increased from -47.01 (Mar 24) to 4.81, marking an increase of 51.82.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.03. This value is below the healthy minimum of 10. It has increased from -30.18 (Mar 24) to 2.03, marking an increase of 32.21.
- For Return On Assets (%), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 5. It has increased from -18.07 (Mar 24) to 1.82, marking an increase of 19.89.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.53 (Mar 24) to 0.40, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.61 (Mar 24) to 0.60, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.28 (Mar 24) to 0.10, marking a decrease of 0.18.
- For Current Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 2.11 (Mar 24) to 1.80, marking a decrease of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.80, marking a decrease of 0.30.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. It has decreased from 26.64 (Mar 24) to 0.00, marking a decrease of 26.64.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.58. This value is within the healthy range. It has increased from -130.94 (Mar 24) to 5.58, marking an increase of 136.52.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has increased from -133.26 (Mar 24) to 8.85, marking an increase of 142.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23.07. It has decreased from 28.95 (Mar 24) to 23.07, marking a decrease of 5.88.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.39. This value exceeds the healthy maximum of 3. It has increased from 1.74 (Mar 24) to 4.39, marking an increase of 2.65.
- For EV / EBITDA (X), as of Mar 25, the value is 36.72. This value exceeds the healthy maximum of 15. It has increased from -3.36 (Mar 24) to 36.72, marking an increase of 40.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 2.27, marking an increase of 1.22.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.65, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 1.05 (Mar 24) to 2.27, marking an increase of 1.22.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from -0.50 (Mar 24) to 0.07, marking an increase of 0.57.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaxtex Cotfab Ltd:
- Net Profit Margin: 16.81%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.03% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.81% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.8
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.4 (Industry average Stock P/E: 398.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.81%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Textiles - General | J-03 (GF to 4th Floor) Tejendra Arcade, Nr, Ganjifarak Mill Compound, Ahmedabad Gujarat 380023 | vaxtexcotfab@gmail.com www.vaxtexcotfabltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aakash Rajeshbhai Thakor | Managing Director |
| Mr. Devi Singh | Non Executive Director |
| Mr. Pranav Vajani | Independent Director |
| Mr. Ravi Jitendra Modi | Independent Director |
| Mr. Harsh Mahendrakumar Kothari | Independent Director |
| Ms. Hardika Ladha | Independent Director |
FAQ
What is the intrinsic value of Vaxtex Cotfab Ltd?
Vaxtex Cotfab Ltd's intrinsic value (as of 09 October 2025) is 0.71 which is 31.07% lower the current market price of 1.03, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹18.9 Cr. market cap, FY2025-2026 high/low of 1.31/0.60, reserves of ₹-0.04 Cr, and liabilities of 48.47 Cr.
What is the Market Cap of Vaxtex Cotfab Ltd?
The Market Cap of Vaxtex Cotfab Ltd is 18.9 Cr..
What is the current Stock Price of Vaxtex Cotfab Ltd as on 09 October 2025?
The current stock price of Vaxtex Cotfab Ltd as on 09 October 2025 is 1.03.
What is the High / Low of Vaxtex Cotfab Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaxtex Cotfab Ltd stocks is 1.31/0.60.
What is the Stock P/E of Vaxtex Cotfab Ltd?
The Stock P/E of Vaxtex Cotfab Ltd is 18.4.
What is the Book Value of Vaxtex Cotfab Ltd?
The Book Value of Vaxtex Cotfab Ltd is 1.00.
What is the Dividend Yield of Vaxtex Cotfab Ltd?
The Dividend Yield of Vaxtex Cotfab Ltd is 0.00 %.
What is the ROCE of Vaxtex Cotfab Ltd?
The ROCE of Vaxtex Cotfab Ltd is 1.77 %.
What is the ROE of Vaxtex Cotfab Ltd?
The ROE of Vaxtex Cotfab Ltd is 4.74 %.
What is the Face Value of Vaxtex Cotfab Ltd?
The Face Value of Vaxtex Cotfab Ltd is 1.00.